statins

Phenol, 2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-, 1,1'-(hydrogen phosphate) is a compound that is a phosphoric acid derivative of compound statins.

Mevastatin (ML236B) is an HMG-CoA reductase inhibitor that was initially isolated from the mold Pythium ultimum. Mevastatin was the first statin to enter clinical trials.

Atorvastatin strontium is used primarily for lowering blood cholesterol and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.Atorvastatin is also used for the treatment of dyslipidemia.

Bempedoic acid-d4 is a deuterated compound of Bempedoic acid. Bempedoic acid has a CAS number of 738606-46-7. ETC-1002, also known as ESP-55016 and Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. Bempedoic acid is absorbed rapidly in the small intestine and enters the liver through cell surface receptors different from those transporters that selectively take up statins. Bempedoic acid is a regulator of lipid and carbohydrate metabolism.

Atorvastatin magnesium trihydrate is used primarily for lowering blood cholesterol and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.Atorvastatin is also used for the treatment of dyslipidemia.

HMG499 is a potent and selective HMG-CoA reductase inhibitor with an IC50 of 0.41 μM, capable of eliminating statins-induced accumulation of HMGCR, lowering serum cholesterol levels, and decreasing atherosclerosis [1].

Bempedoic acid (ETC1002) is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies. Bempedoic acid(ETC1002) is absorbed rapidly in the small intestine and enters the liver through cell surface receptors different from those transporters that selectively take up statins. Bempedoic acid(ETC1002) is a regulator of lipid and carbohydrate metabolism.

Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class.

Bemfivastatin hemicalcium (PPD 10558), an orally active HMG-CoA reductase inhibitor, serves as a lipid-lowering agent. It amplifies liver extract activity and exhibits no-observed adverse effect levels (NOAEL) at dosages of ≥320 mg/kg/d for rat developmental toxicity, ≥12.5 mg/kg/d for rabbit maternal toxicity, and ≥25 mg/kg/d for rabbit developmental toxicity. This compound is utilized in research concerning hypercholesterolemic myalgia in patients intolerant to statins.

Dalotuzumab (MK-0646) is a humanized recombinant monoclonal antibody (IgG1 type) that targets IGF-1R, inhibiting tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation mediated by IGF-1 and IGF-2. It induces apoptosis and cell cycle arrest, and its antitumor activity is significantly enhanced when used alongside other anticancer agents like statins, both in vitro and in vivo [1] [2] [3].